Ark. judge fines J&J and unit $1.2B over Risperdal marketing

04/11/2012 | CNNMoney

An Arkansas judge said Johnson & Johnson and unit Janssen Pharmaceuticals must pay $1.2 billion for violating the state's False Claims and Deceptive Trade Practices acts in regard to marketing antipsychotic Risperdal. The penalty signals that big drugmakers "cannot lie to the FDA, patients and doctors in order to defraud Arkansas taxpayers of our Medicaid dollars," Arkansas Attorney General Dustin McDaniel said. A spokeswoman for Janssen said evidence showed the firms acted legally, and they will appeal.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD